Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00782626
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:50.390594+00:00
Published At
2016-02-02T00:00:00+00:00
Record Updated At
2018-08-15
Results Posted At
2016-02-02
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Glioma", "Low-grade Glioma", "Astrocytoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-08-15"
protocolSection.identificationModule.nctId
"NCT00782626"
protocolSection.identificationModule.officialTitle
"A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2016-02-02"

Study condition terms

  • Glioma (protocolSection.conditionsModule.conditions)
  • Low-grade Glioma (protocolSection.conditionsModule.conditions)
  • Astrocytoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.